SLC5A5 and thyroid gland carcinoma: Because constitutive activation of the MAPK pathway in thyroid cancer frequently represses NIS expression and function and is associated with decreased radioiodide uptake and poor patient prognosis, many studies have focused on MAPK inhibitors (Dunn et al., 2019; Ho et al., 2013).